Navigation Links
Ad de Waard Appointed Vice President of International Sales and Marketing at Accumetrics, Inc.
Date:12/16/2008

SAN DIEGO, Dec. 16 /PRNewswire/ -- Accumetrics, Inc. has appointed 20-year industry veteran Ad de Waard as Vice President of International Sales and Marketing.

"Ad joins us at an important juncture in the evolution of Accumetrics, as we are now well-positioned to expand our international business," says Timothy I. Still, President and CEO at Accumetrics. "His extensive experience in managing global distribution networks will be invaluable as we continue on our growth path and expand our capabilities to provide Accumetrics' products to customers worldwide."

Mr. de Waard has more than 20 years' experience in the in-vitro diagnostics industry in roles of increasing responsibility involving international sales and marketing and general management. He has launched several new cardiovascular products, including products in the area of platelet function analysis.

Prior to Accumetrics, Mr. de Waard served as Director of International Business Development at Inverness, Inc., which acquired HemoSense, Inc. in 2007. Prior to his time at HemoSense, he held various international marketing positions, including those at Dade Behring and Amersham International. In his new position at Accumetrics, Mr. de Waard will be based in the Netherlands.

Mr. de Waard holds several degrees and certificates, including his HBO (the Dutch equivalent of a bachelor degree) from the School of Clinical Chemistry, The Netherlands, MBO certificates in process chemistry and electrotechnology, and completion of the marketing program at the Netherlands Institute of Marketing.

AboutAccumetrics(www.accumetrics.com)

Accumetrics is committed to advancing medical understanding of p
'/>"/>

SOURCE Accumetrics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Dr. Allen Woolf Appointed Chief Medical Officer For CIGNA Group Insurance
2. William Moore Appointed to IRIDEX Board of Directors
3. Roy Jakobs Appointed Elsevier Managing Director, A&G Sales and Customer Marketing
4. Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
5. James B. Hawkins Appointed to IRIDEX Board of Directors
6. Bryan R. Rogers Appointed President of Far West Division
7. Theodore A. Boutacoff Appointed President & CEO of IRIDEX
8. Catholic Health Association Disappointed by Failure to Override SCHIP Veto
9. Steven M. Safyer, MD, Appointed President and CEO of Montefiore Medical Center
10. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
11. Irene Hegeman Richard, MD, Appointed Senior Medical Advisor to The Michael J. Fox Foundation

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...na, Nov. 9 /PRNewswire-Asia-FirstCall/ -- Mindray ...ing developer, manufacturer and,marketer of medica...unaudited,financial results for the third quarter ...Highlights for Operations as of September 30, 2009...1 million, an increase of, 3.1% over the thi...
(Date:11/9/2009)...ks President Obama,s promise to not expand abortio... Bishops still concerned for poor, elderly ,, ...inal Francis George of Chicago, president of the U...d the November 7 decision of the U.S. House of Rep...oney from paying for elective abortions. ,, In...
(Date:11/9/2009)... Studying Genetic Variance Across the World is C... (Vocus) November 9, 2009 --...xtraordinarily valuable when analyzing and interpr...ics study that scanned the genomes of 4,000 peopl...rences, Drs. Chao Tian and Michael F. Seldin of th...
(Date:11/9/2009)...new cells regained sexual function, study says,...Researchers were able to restore sexual function t...le tissue in the lab and implanting it, a new stud...ys off, researchers say the technique could one da...men. , "We were able to show the tissue was abl...
(Date:11/9/2009)... Course, to be Offered in April 2010, Provides F... Cambridge, MA (Vocus) November 9,...an Rights (PHR) first inspected a suspected mass ...d he would need a team of experts to help interpre...perly was a key first step in securing evidence of...
Breaking Medicine News(10 mins):Health News:Mindray Announces Third Quarter 2009 Financial Results 2Health News:Mindray Announces Third Quarter 2009 Financial Results 3Health News:Mindray Announces Third Quarter 2009 Financial Results 4Health News:Mindray Announces Third Quarter 2009 Financial Results 5Health News:Mindray Announces Third Quarter 2009 Financial Results 6Health News:Mindray Announces Third Quarter 2009 Financial Results 7Health News:Mindray Announces Third Quarter 2009 Financial Results 8Health News:Mindray Announces Third Quarter 2009 Financial Results 9Health News:Mindray Announces Third Quarter 2009 Financial Results 10Health News:Mindray Announces Third Quarter 2009 Financial Results 11Health News:Mindray Announces Third Quarter 2009 Financial Results 12Health News:Mindray Announces Third Quarter 2009 Financial Results 13Health News:Mindray Announces Third Quarter 2009 Financial Results 14Health News:Mindray Announces Third Quarter 2009 Financial Results 15Health News:Mindray Announces Third Quarter 2009 Financial Results 16Health News:Mindray Announces Third Quarter 2009 Financial Results 17Health News:Mindray Announces Third Quarter 2009 Financial Results 18Health News:Cardinal George Lauds House Action to Ban Federal Funds for Abortion; Promises Vigilance as Senate Pursues Health Care Reform, Wary About Affect on Poor, Elderly 2Health News:Cardinal George Lauds House Action to Ban Federal Funds for Abortion; Promises Vigilance as Senate Pursues Health Care Reform, Wary About Affect on Poor, Elderly 3Health News:News from the November/December Issue of Molecular Medicine 2Health News:Scientists Grow New Penile Tissue in the Lab 2Health News:Scientists Grow New Penile Tissue in the Lab 3Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 2Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 3Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 4
...N.J., Dec. 12 Alfacell Corporation (Nasdaq: AC...president, chief financial officer and corporate s...s of today. Mr. Kenyon will remain on the board o... Kenyon has accepted a full time position as execu...
...ass., Dec. 12 Millennium Research Group (MRG) ana...ished G lobal Markets for Hyaluronic Acid Viscos...fer extensive expertise on the recent FDA premarke...s available to comment on: , , , , ...
..., Dec. 12 Ogilvy Public Relations Worldwide (Ogi... announced today that it has been awarded a five-y...with the National Cancer Institute (NCI), Office o...,s life sciences consulting subsidiary, Feinstein ...
...hase 3 Program Expected to Begin in December - , ...rmaceuticals, a division of Wyeth (NYSE: WYE ), ...inical trial of neratinib (HKI-272) in women with ...the ErbB-2 receptor (also known as HER-2 or Neu). ...
...s not sure whether one causes the other, or one is...2 (HealthDay News) -- Adults who have panic disord...t attacks and heart disease, but not heart-related...than 347,000 adults without the condition. , Peopl...
...ec. 12 The Female Health Company (NYSE Alternex...Administration,s (FDA) Obstetrics and Gynecology D...at the company,s second-generation female condom, ...ondition that the FC2 Female Condom,s instructions...
Other Medicine News:Health News:Alfacell Announces Management Update 2Health News:Alfacell Announces Management Update 3Health News:Millennium Research Group Analyst Available to Comment on FDA's Premarket Approval Recommendation of Genzyme Biosurgery's Synvisc Single-Injection Product for the Knee 2Health News:National Cancer Institute Selects Ogilvy Public Relations Worldwide for Comprehensive Multi-Year Communications Support 2Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 2Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 3Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 4Health News:Panic Disorder Linked to Higher Risk of Heart Disease 2Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 2Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 3Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 4Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 5
(Date:11/9/2009)..., NATICK, Mass., Nov. 9 /PRNewswire-FirstCall/ ...ay announced its schedule of events at the 38th an...logy (AAGL), which runs from November 15-19 in Orl...will be presented featuring the Company,s Urology/...truction systems and mid-urethral sling systems us...
(Date:11/9/2009)..., NEW YORK, Nov. 9 /PRNewswire-Asia-FirstCa...E: AOB ), ("the Company" or "AOBO"), a pharmaceut... the development, manufacture and,commercializatio...unter ("OTC"),products, today announced that it pl...s on Monday, November 16, 2009, after the market c...
(Date:11/9/2009)..., SAN DIEGO, Nov. 9, 2009 /PRNewswire-FirstCall...today reported financial results for the third qua...d a lower net loss allocable to common stockholder...r $0.38 per share, compared to a net loss allocabl...008 of $56.2 million, or $0.76 per share, and a ne...
Breaking Medicine Technology:Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 2Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 3Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 4Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 5Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 2Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 3Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 4Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 5Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 6Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 7Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 8Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 9Exercise 30 Minutes a Day 3F Who Knew 21 58468 1Exercise 30 Minutes a Day 3F Who Knew 21 58468 2Boston University School of Medicines black womens health study receives 249 1 million award 58465 1Book by UCR biologist tells story of 100 year quest for elusive malaria vaccine 58462 1Book by UCR biologist tells story of 100 year quest for elusive malaria vaccine 58462 2Book by UCR biologist tells story of 100 year quest for elusive malaria vaccine 58462 3Book by UCR biologist tells story of 100 year quest for elusive malaria vaccine 58462 4
EBI OsteoGen™-M (Mesh Cathode)
Interference Screws
...crew is indicated for graft fixation in Orthopaedi...s with bone-patellar tendon-bone or soft tissue au...es easy and atraumatic insertions with excellent g...-Reinforced 96L/4D copolymer combines optimal stre...
PHANTOM SofThread Cannulated Interference Screws
Medicine Products: